Mixed leukocyte suspensions, containing 106 leukocytes per ml, were prepared from dog peripheral blood by dextran sedimentation. Lysates of these suspensions, prepared by sonification, were administered intravenously to the autologous dogs. The plasma histamine levels were increased to an average value 320% above the control values (P < 0.001). The individual elements in the mixed leukocyte suspensions were separated by sucrose gradient and glass bead column fractionation procedures, and purified suspensions of platelets (no other formed elements present), lymphocytes (95 to 100%), and granulocytes (90 to 98%) were obtained. Lysates of these suspensions all had significant histamine-releasing activity when administered intravenously to dogs. Although leukocytes and platelets from other species are known to harbor mediators of histamine release, this study provides the first demonstration of the histamine-releasing activity of dog leukocytes and platelets. Many of the studies of leukocyte and platelet histamine-releasing factors have employed in vitro systems leaving the in vivo role of these factors in doubt. The present studies provide evidence that leukocyte and platelet histamine-releasing factors have in vivo activity.
Histamine, a potent biological amine, has been implicated in the mediation of several important phenomena including inflammation, allergic reactions, and shock (11) . Histamine is stored largely in the granules of mast cells and circulating basophils or platelets, and its release from these stores may be important in initiating immunological injuries and the inflammatory response. Accordingly, the mechanisms responsible for histamine release have received a great deal of attention in recent years, and various materials, including cationic proteins (12) , antigens (6) , and compounds such as 48/80 (4) , have proven to be potent histamine-releasing agents.
Cationic proteins from human platelets have been shown to release (8) histamine from rat mast cells. In previous studies (5), we demonstrated that extracts of human platelets and of purified human lymphocytes and granulocytes released histamine from human leukocytes in vitro. The present studies were initiated to determine if leukocyte extracts could release histamine in vivo in the intact dog.
MATERIALS AND METHODS
Leukocytes were prepared for use in this study as follows. Blood was drawn through 18-gauge needles into heparinized syringes and transferred to polypropylene centrifuge tubes containing one part sedimentation fluid and two parts blood. The sedimentation fluid contained 3% dextran (molecular weight, 188,000) in 2.5% glucose and normal saline with 20 units of heparin/ml or 0.017 M ethylenediaminetetraacetic acid (EDTA) as anticoagulant. After mixing, the erythrocytes were allowed to sediment two-thirds the length of the tube at room temperature. The resulting platelet and leukocyte-rich supernatant fluid was aspirated and centrifuged at 150 X g for 10 min at room temperature (model SP/x, Ivan Sorvall, Inc., Norwalk, Conn.), and the pelleted leukocytes and platelets were used as outlined below.
Purified suspensions of platelets were prepared as follows. A 150-g platelet-leukocyte button, prepared as above, was washed in tris(hydroxymethyl)aminomethane (Tris)-albumin (6) buffer and resuspended in a final volume of 5 ml of Tris A. This suspension was layered over two discontinuous sucrose gradients composed of 4-ml layers of 40, 35, 30, 25, 20, and 15% sucrose in Tris A. The gradients were centrifuged at 150 X g for 6 min at 2 C in a swinging bucket rotor (model PR-2 or B-20, International Equipment Co., Needham Heights, Mass.). The leukocyte and erythrocyte-free platelet bands which formed at the tops of the gradients were aspirated and centrifuged at 2,500 X g for 30 min at 2 C. The platelet buttons were resuspended in 20 ml of cold Tris A.
Suspensions of purified lymphocytes and granulocytes were prepared by using a glass bead column technique essentially the same as that described by Plasma histamine levels were determined as described previously (3). The initial plasma histamine levels ranged from 0.028 to 0.088 mg/ml, which is within the previously reported range (3) . The student t test was used for statistical analyses.
RESULTS
Leukocytes were separated from 30 ml of blood from each of 10 dogs and resuspended at 106 cells per ml in Tris A buffer. These suspensions contained appreciable numbers of platelets, lymphocytes, monocytes, and granulocytes as well as erythrocytes. Lysates of these dilute suspensions contained 0.6 to 1.5 mg of protein per ml, but they did not contain detectable levels of histamine. Each dog was injected with undiluted autologous leukocyte lysate, and the plasma histamine levels, aortic pressures, and heart rates were determined.
In all 10 experiments, the plasma histamine level increased significantly after the leukocyte lysate injection (Table 1 ). The average maximum increase in plasma histamine level for the 10 dogs was 0.144 jig of histamine per ml. Control dogs were injected with buffer alone, and they displayed only minor changes in plasma histamine level. There were no significant changes in aortic pressure or heart rates in either control dogs or dogs injected with leukocyte lysate.
Although all of the dogs injected with leukocyte lysate had appreciable increases in plasma histamine, they did not all respond in the same manner. Five dogs had a rapid rise in plasma histamine level to a peak at 2 min, whereas the remaining five dogs had a gradual increase in plasma histamine with a peak of approximately the same magnitude at 30 min (Fig. 1) .
To determine which of the formed elements in the mixed leukocyte lysates was responsible for the increase in plasma histamine observed after injection, purified platelet, lymphocyte, and granulocyte suspensions were prepared. Lysates of these suspensions contained 0.7 to 1.3 mg of protein per ml, but they did not contain detect- The combination of elements in the mixed leukocyte lysate produced the greatest histamine release, but the purified platelets, lymphocytes, and granulocytes had significant individual histamine-releasing activity ( Table 2 ). The differences in histamine-releasing activity were not due to differences in cell or protein concentrations in the lysates. Once again, in spite of the large increases in plasma histamine, the aortic pressure and heart rate had only insignificant variations.
Intradermal injection of 0.1 ml of a lysate of 107 white blood cells per ml was followed by immediate wheal of 1.2 X 1.0 cm with flare but without pseudopods. Intradermal injection of 0.1 ml of lysate of 106 white blood cells or less was not followed by reactions greater than that which followed intradermal injection of buffer alone. After the intradermal injection of 0.1 ml of 48/80 at concentrations of 5, 2.5, or 1.25 mg/ml, immediate wheals of 1.7 X 1.8 cm were observed with increased flare and pseudopods. (6) , and rat eosinophil peroxidase has been implicated as a mediator of histamine release (2) . Also compounds such as 48/80 (4), arginine or lysinerich histones, and poly-1-lysine (10) are potent releasing agents. Although some of these substances may be responsible for the histaminereleasing activity in dog leukocytes and platelets, definitive information on the nature of this activity must await fractionation and purification of the active factors involved. These studies are also of interest in relation to the cardiovascular effects of endogenous histamine. In a previous study (3) , it was demonstrated that infusion of compound 48/80 into normal dogs was followed by prompt evaluation of plasma histamine levels and marked cardiovas-cular alterations culminating in shock and acidosis. The physiological alterations observed were attributed to the effects of the liberated histamine. The average maximum per cent increase in plasma histamine in that study was 135%, whereas the mean increase in the present study was about 300%. After 48/80 infusion, the aortic pressure decreased by 71 % and the heart rate decreased by 15%, whereas these variables increased by an average of 6 and 9%, respectively, after leukocyte lysate infusion. Therefore, the response obtained after compound 48/80 infusion may have been due to other pharmacological effects of 48/80 or to release of high concentration of histamine from mast cells in close proximity to blood vessels.
The limited skin reaction after intradermal injection of white blood cell lysates at concentrations 10 times higher than those used intravenously suggests that white blood cell lysates may not be highly active in releasing histamine from mast cells.
